Cosmetics firms that market products used in and around the eye and firms that also manufacture drugs are more likely targets for FDA inspections and enforcement action, according to Karyn Campbell, director of the investigations branch at the agency’s Philadelphia District Office.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?